IO Biotech, Inc. Forecasted to Earn FY2022 Earnings of ($2.39) Per Share (NASDAQ:IOBT)

IO Biotech, Inc. (NASDAQ:IOBTGet Rating) – Investment analysts at HC Wainwright issued their FY2022 earnings estimates for IO Biotech in a research report issued to clients and investors on Monday, November 21st. HC Wainwright analyst E. Bodnar expects that the company will post earnings per share of ($2.39) for the year. HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for IO Biotech’s current full-year earnings is ($2.30) per share. HC Wainwright also issued estimates for IO Biotech’s Q4 2022 earnings at ($0.60) EPS, FY2023 earnings at ($3.42) EPS, FY2024 earnings at ($1.98) EPS, FY2025 earnings at ($1.36) EPS and FY2026 earnings at ($1.04) EPS.

IO Biotech Price Performance

IOBT opened at $2.68 on Wednesday. The company’s 50 day moving average is $2.63 and its 200 day moving average is $3.79. IO Biotech has a 12-month low of $2.15 and a 12-month high of $12.58.

Institutional Investors Weigh In On IO Biotech

A number of institutional investors and hedge funds have recently added to or reduced their stakes in IOBT. Victory Capital Management Inc. bought a new stake in IO Biotech during the 3rd quarter worth approximately $119,000. Psagot Value Holdings Ltd. Israel bought a new stake in IO Biotech during the 3rd quarter worth approximately $111,000. Citadel Advisors LLC raised its stake in IO Biotech by 192.4% during the 3rd quarter. Citadel Advisors LLC now owns 42,180 shares of the company’s stock worth $114,000 after acquiring an additional 27,754 shares during the period. Renaissance Technologies LLC bought a new stake in IO Biotech during the 3rd quarter worth approximately $50,000. Finally, Jane Street Group LLC bought a new stake in IO Biotech during the 1st quarter worth approximately $76,000. Institutional investors own 53.64% of the company’s stock.

About IO Biotech

(Get Rating)

IO Biotech, Inc, a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer.

See Also

Earnings History and Estimates for IO Biotech (NASDAQ:IOBT)

Receive News & Ratings for IO Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IO Biotech and related companies with MarketBeat.com's FREE daily email newsletter.